ArticlePloS one2026
FSTL1 promotes dendritic cell pyroptosis and immunosuppression in sepsis by inhibiting STING autophagy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-induced immunosuppression, characterized by dendritic cell (DC) depletion, correlates with poor outcomes. The glycoprotein FSTL1 is elevated in sepsis, but its contribution to DC pyroptosis and subsequent immune dysfunction remains unknown.
methodsWe utilized in vitro models with splenic DCs and mouse dendritic cell line DC2.4, alongside a murine cecal ligation and puncture (cecal ligation and puncture) sepsis model. The roles of STING and autophagy were probed using specific modulators (STING agonist DMXAA; STING specific inhibitor C-176; autophagy inhibitor 3-methyladenine). Pyroptosis was assessed by quantifying cleaved CASP1 and GSDMD-N via Western blotting and flow cytometry. STING pathway activation and autophagic flux were evaluated by detecting protein phosphorylation (p-STING, p-TBK1) and key markers (LC3B, P62) through Western blotting, immunofluorescence, and co-immunoprecipitation. DC-mediated T-cell responses were determined by proliferation assays and cytokine secretion analysis.
resultsFSTL1 was found elevated and correlated withDC pyroptosis in vitro and in septic mice. Mechanistically, FSTL1 inhibited the autophagic degradation of STING, leading to its accumulation and subsequent activation. Consequently, this impaired T-cell priming capacity and resulted in immunosuppression in vivo. Inhibition of STING attenuated FSTL1-induced pyroptosis, restored DC-mediated T-cell activation, and ameliorated immunosuppression. In murine septic models, FSTL1 exacerbated multiple organ injury and increased mortality, effects that were reversed by STING inhibition.
conclusionOur findings demonstrate that FSTL1 correlates with impaired STING autophagic degradation and DC pyroptosis, suggesting a potential pathway contributing to septic immune dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.